SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional ...

In a bid to boost its foothold in oncology, Merck KGaA late last month announced a deal to purchase cancer-focused Pfizer spinout SpringWorks Therapeutics for $3.9 billion. The health of Merck ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

The bottom line: As we anticipate the announced acquisition of Springworks to close, we updated our model, changing our fair value estimate for narrow-moat Merck KGaA to EUR 142 from EUR 148.

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Merck KGaA operates in three key segments ... as contributions from new products introduced through the SpringWorks acquisition offset moderate declines in Merck’s mature portfolio—including ...

FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing the macro-economic and geopolitical environment as well ...

NEW YORK/FRANKFURT (Reuters) -Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of ...

In other recent news, SpringWorks Therapeutics has been in the spotlight with several key developments. The company is set to be acquired by Merck (NSE:PROR) KGaA, a move that TD Cowen analysts ...

In other recent news, SpringWorks Therapeutics has been in the spotlight with several key developments. The company is set to be acquired by Merck (NSE:PROR) KGaA, a move that TD Cowen analysts ...

SpringWorks Therapeutics, a U.S.-based clinical-stage biopharmaceutical company, has been acquired by German pharmaceutical giant Merck KGaA in a $3.7 billion deal. Announced in early 2025, the ...